Jingfang Ju

This paper develops a multimodal miR-15a-based therapeutic that overcomes resistance to gemcitabine and daraxonrasib in PDAC by combining gene regulation and nucleotide metabolism disruption, showing potent antitumor effects in vitro and in vivo.

This paper develops Gem-miR-15a, a gemcitabine-modified microRNA, which overcomes 5-FU and oxaliplatin resistance in colorectal cancer with high potency and low toxicity.

This paper develops a multimodal miR-15a mimic to overcome PARP inhibitor resistance in ovarian cancer, showing synergy with olaparib and antitumor efficacy.

Yuen and Hwang et al. developed Gem-modified miRNA mimics that show enhanced efficacy in inhibiting PDAC cell growth and tumor progression with reduced toxicity.